<DOC>
	<DOC>NCT01486628</DOC>
	<brief_summary>It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers. Objectives are to determine: 1. the maximal tolerated dose of SC ND-0612 2. the steady state plasma concentration of LD and CD following SC ND-0612 administration. Each treatment group will include 6 healthy volunteers. Dosing will be done in a sequential manner.</brief_summary>
	<brief_title>Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Healthy Caucasian males between 18 and 40 years (inclusive) of age Normal BMI (18.524.9) Subjects with negative urinary drugs of abuse, HIV, Hepatitis B or Hepatitis C serology tests Subjects must be able to adhere to the protocol requirements Subjects must provide written informed consent to participate in the study. History of significant psychiatric disorder, neurological diseases or sleep disorders History of significant systemic diseases, by medical history or tests performed during screening examinations Clinically significant laboratory tests at screening History of drug or alcohol abuse. Allergy to levodopa, carbidopa or any inactive component of the test formulation. Subjects with dark skin Subjects with skin diseases or neoplasms Subjects with narrowangle glaucoma Subjects with significant allergic response to other drugs. Presence of clinically significant scars or other skin disorders in the area of placement of the pump. Use of any prescription or overthecounter (OTC) medications Subjects who donated blood or received blood, in the last 3 months Participation in another clinical trial in the last 30 days Subjects which do not have the ability to communicate well or will not adhere to the protocol procedures</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>